Galapagos(GLPG) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total operating profit from continuing operations amounted to EUR 295.1 million in 2025, compared to an operating loss of EUR 188.3 million in 2024, primarily due to the release of EUR 1,069 million in deferred income related to Gilead [8][9] - Financial investments in cash and cash equivalents totaled EUR 2,998 million on December 31, 2025, down from EUR 3,317.8 million on December 31, 2024 [11] - The company expects to have approximately EUR 2.775 billion to EUR 2.85 billion in cash equivalents and financial investments by December 31, 2026 [15] Business Line Data and Key Metrics Changes - The decision to wind down cell therapy activities resulted in operating expenses of EUR 399.8 million, including an impairment of EUR 228.1 million and severance costs of EUR 33.3 million [10] - The company is evaluating strategic options for its legacy R&D asset, GLPG3667, which met primary endpoints in clinical studies [6][7] Market Data and Key Metrics Changes - The company has transitioned a significant portion of its cash holdings to US dollars, now holding approximately 72% in USD and 28% in euros, reflecting a strategic shift based on expected business development activities [12][47] Company Strategy and Development Direction - The company is focused on a transformative strategy, moving away from cell therapy and aiming for long-term value creation through business development opportunities [4][5] - Collaboration with Gilead is seen as a key strategic advantage, providing a platform for future growth and deal-making [6][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline of opportunities and emphasized a disciplined approach to capital allocation [16] - The company aims to be cash flow neutral to positive by the end of 2026, despite ongoing restructuring costs [14][50] Other Important Information - The company expects the wind down of cell therapy activities to be substantially completed by the end of Q3 2026, with a one-time restructuring cash impact of EUR 125 million to EUR 175 million in 2026 [13][14] Q&A Session Summary Question: Business development strategy and Gilead agreement - Management confirmed that the strategy remains focused on de-risking late-stage clinical assets, particularly in the I&I and oncology space, without setting a specific deadline for deals [18][20][21] Question: Update on GLPG3667 development - Management reiterated a high bar for internal development versus out-licensing, emphasizing ongoing discussions with potential partners [25][26][27] Question: Capital allocation and Gilead partnership - Management highlighted that the EUR 3 billion capital must account for both acquisitions and development expenses, with Gilead potentially contributing to deal terms and development costs [31][33] Question: Future of cell therapy wind down costs - Management indicated that while the range for restructuring costs has been lowered, future updates will be provided as the wind down progresses [40][42] Question: Cash allocation strategy and breakeven expectations - Management expects to be cash flow neutral or positive by year-end, with ongoing costs impacting quarterly results [49][50]